Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. EMEA Innovative Medicine /
      2. Our innovation/
      3. Focus areas /
      4. Neuroscience/
      5. Neuropsychiatric disorders

      Neuropsychiatric disorders

      Approximately 40 million people across the EU are living with depression and it is the leading cause of disability and disease burden worldwide.[5][6] In an area of high unmet need[6] our medications and innovations have helped improve the quality of care for millions of people living with neuropsychiatric disorders. However, there is a lot more work to be done.

      Achieving response and remission with treatment in major depressive disorder (MDD) requires time and effort, which in turn prolongs patient suffering.[7][8][9] Access to innovative treatments for neuropsychiatric disorders remains the best way to address suboptimal outcomes for patients.[10][11]

      We’re committed to using emerging science to develop novel therapies for the treatment of severe mood disorders, and are expanding our focus to include the full range of psychosis spectrum disorders and mood dysregulation.
      Breaking depression .webp

      Breaking Depression

      Breaking Depression aims to raise awareness of the challenges of living with different types of depression, including MDD, and provides practical tools to help everyone start the right conversations with their loved ones and healthcare professionals to get the right support. The campaign has been started by Janssen, with support from the Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe) and the European Federation of Associations of Families of People with Mental Illness (EUFAMI).

      By broadening our understanding of the different types of depression, we can all work together to help break depression for good.
      Pledge your support
      Woman hiking .webp

      The Little Book of Big Conversations

      Developed in partnership with GAMIAN-Europe and EUFAMI, The Little Book of Big Conversations is a digital book containing practical advice to help people start conversations about depression. Open and honest conversations about depression are an important step towards ensuring that people get the support they need. However, we understand that starting these conversations can be daunting and knowing where to begin can be difficult.
      Open the book
      Couple biking .webp

      Plan your way out of depression

      Everyone’s route out of depression is different, however the journey can be more difficult if made alone. Seeking help and finding ways to cope with depression can be helpful in a person’s journey out of depression. Whatever route taken, supportive conversations with a doctor or another healthcare professional are often crucial. This is why we have partnered with GAMIAN-Europe and EUFAMI to create a free guide with practical tips to support people living with depression, and their caregivers, in getting the most out of each step in their journey but most importantly persevering towards recovery.
      Open your guide

      References
      [1]Deuschl G, et al. The burden of neurological diseases in Europe: An analysis for the Global Burden of Disease Study 2017. Lancet Public Health. 2020;5(10):E551-E567.
      [2]Open Access Government 2019. Tackling the growing burden of brain disorders in Europe. Available at: https://www.openaccessgovernment.org/brain-disorders-in-europe/72909/. Last accessed July 2023.
      [3]GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2018;392:1789-1858.
      [4]PsychGuides.com. Neurological Problem Symptoms, Causes and Effects. Available at: https://www.psychguides.com/neurological-disorders/ . Last accessed July 2023.
      [5]WHO. Depression and other common mental disorders. Available at: WHO-MSD-MER-2017.2-eng.pdf Last accessed July 2023.
      [6]WHO. Fact sheets. Depression. Available at https://www.who.int/news-room/fact-sheets/detail/depression . Last accessed July 2023.
      [7]Machado-Viera R, et al. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals. 2010;3(1):19–41.
      [8]Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges and future directions. Patient Pref Adherence. 2012;6:369–388.
      [9]Demyttenaere K & Van Duppen D. The Impact of (the Concept of) Treatment-Resistant Depression: An Opinion Review. Int J Neuropsychopharmacol 2019;22(2):85–92.
      [10]Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-17.
      [11]Heerlein K, Perugi G, Otte C, et al. Real-world evidence from a European cohort study of patients with treatment resistant depression: Treatment patterns and clinical outcomes. J Affect Disord. 2021;290:334-344.

      CP-459038
      September 2024